Aligos Historical Balance Sheet

ALGS Stock

USD 22.99 1.64 7.68%

Trend analysis of Aligos Therapeutics balance sheet accounts such as Short Long Term Debt Total of 10.6 M, Other Current Liabilities of 11.7 M or Total Current Liabilities of 27.1 M provides information on Aligos Therapeutics' total assets, liabilities, and equity, which is the actual value of Aligos Therapeutics to its prevalent stockholders. By breaking down trends over time using Aligos Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Aligos Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aligos Therapeutics is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aligos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.

About Aligos Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Aligos Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Aligos Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Aligos Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Aligos currently owns. An asset can also be divided into two categories, current and non-current.

Aligos Therapeutics Balance Sheet Chart

At this time, Aligos Therapeutics' Common Stock Shares Outstanding is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 193.5 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 11.7 M in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Non Current Liabilities Total

Add Fundamental

Total Assets

Total assets refers to the total amount of Aligos Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aligos Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Aligos Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aligos Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Aligos Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Aligos Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aligos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.At this time, Aligos Therapeutics' Common Stock Shares Outstanding is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 193.5 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 11.7 M in 2024.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	14.5M	12.6M	11.1M	10.6M
Total Assets	235.4M	146.7M	151.5M	193.1M

Short Long Term Debt Total Total Assets

Aligos Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		-0.32	0.86	0.87	0.91	0.39	0.9	-0.26	0.54	-0.97	-0.6	0.25	0.98	0.42	-0.42	-0.16	0.99	0.76	-0.81	-0.69	-0.32	0.83	0.74	-0.61	0.91	0.5
Short Long Term Debt Total	-0.32		-0.46	-0.45	-0.43	0.22	-0.46	0.94	0.29	0.47	0.81	-0.22	-0.43	0.45	0.11	0.89	-0.36	-0.38	0.67	0.53	1.0	-0.31	-0.63	0.54	-0.43	-0.53
Other Current Liab	0.86	-0.46		0.98	0.93	-0.05	0.94	-0.55	0.47	-0.91	-0.84	0.27	0.91	0.35	-0.27	-0.24	0.84	0.89	-0.9	-0.88	-0.46	0.97	0.95	-0.8	0.93	0.83
Total Current Liabilities	0.87	-0.45	0.98		0.9	0.04	0.9	-0.52	0.59	-0.9	-0.84	0.47	0.9	0.35	-0.39	-0.18	0.85	0.95	-0.86	-0.84	-0.45	0.97	0.92	-0.76	0.9	0.84
Total Stockholder Equity	0.91	-0.43	0.93	0.9		0.11	1.0	-0.44	0.48	-0.93	-0.7	0.21	0.93	0.16	-0.49	-0.18	0.92	0.85	-0.79	-0.92	-0.43	0.87	0.89	-0.88	1.0	0.61
Other Liab	0.39	0.22	-0.05	0.04	0.11		0.1	0.4	0.44	-0.3	0.24	0.14	0.32	0.19	-0.53	0.18	0.43	-0.05	0.02	0.21	0.22	-0.09	-0.13	0.27	0.11	-0.43
Net Tangible Assets	0.9	-0.46	0.94	0.9	1.0	0.1		-0.49	0.44	-0.93	-0.73	0.18	0.93	0.14	-0.47	-0.23	0.91	0.83	-0.81	-0.93	-0.46	0.87	0.91	-0.89	1.0	0.63
Property Plant And Equipment Net	-0.26	0.94	-0.55	-0.52	-0.44	0.4	-0.49		0.24	0.45	0.89	-0.16	-0.42	0.35	0.01	0.83	-0.29	-0.42	0.71	0.6	0.94	-0.42	-0.74	0.6	-0.44	-0.7
Current Deferred Revenue	0.54	0.29	0.47	0.59	0.48	0.44	0.44	0.24		-0.43	-0.16	0.63	0.46	0.47	-0.67	0.58	0.51	0.66	-0.16	-0.34	0.29	0.55	0.37	-0.24	0.48	0.31
Net Debt	-0.97	0.47	-0.91	-0.9	-0.93	-0.3	-0.93	0.45	-0.43		0.73	-0.2	-1.0	-0.33	0.37	0.33	-0.98	-0.76	0.9	0.75	0.47	-0.85	-0.84	0.67	-0.93	-0.59
Retained Earnings	-0.6	0.81	-0.84	-0.84	-0.7	0.24	-0.73	0.89	-0.16	0.73		-0.38	-0.71	-0.03	0.14	0.62	-0.59	-0.75	0.9	0.76	0.81	-0.77	-0.91	0.71	-0.7	-0.9
Accounts Payable	0.25	-0.22	0.27	0.47	0.21	0.14	0.18	-0.16	0.63	-0.2	-0.38		0.18	0.05	-0.55	0.14	0.23	0.64	-0.15	-0.22	-0.22	0.34	0.29	-0.16	0.21	0.43
Cash	0.98	-0.43	0.91	0.9	0.93	0.32	0.93	-0.42	0.46	-1.0	-0.71	0.18		0.35	-0.38	-0.3	0.98	0.75	-0.89	-0.74	-0.43	0.85	0.84	-0.67	0.93	0.58
Non Current Assets Total	0.42	0.45	0.35	0.35	0.16	0.19	0.14	0.35	0.47	-0.33	-0.03	0.05	0.35		0.28	0.35	0.31	0.26	-0.29	0.08	0.45	0.49	0.06	0.19	0.16	0.27
Non Currrent Assets Other	-0.42	0.11	-0.27	-0.39	-0.49	-0.53	-0.47	0.01	-0.67	0.37	0.14	-0.55	-0.38	0.28		-0.24	-0.49	-0.49	0.05	0.44	0.11	-0.21	-0.36	0.42	-0.49	-0.01
Other Assets	-0.16	0.89	-0.24	-0.18	-0.18	0.18	-0.23	0.83	0.58	0.33	0.62	0.14	-0.3	0.35	-0.24		-0.2	-0.01	0.6	0.23	0.89	-0.09	-0.39	0.24	-0.18	-0.32
Cash And Short Term Investments	0.99	-0.36	0.84	0.85	0.92	0.43	0.91	-0.29	0.51	-0.98	-0.59	0.23	0.98	0.31	-0.49	-0.2		0.74	-0.8	-0.71	-0.36	0.79	0.75	-0.64	0.92	0.45
Common Stock Shares Outstanding	0.76	-0.38	0.89	0.95	0.85	-0.05	0.83	-0.42	0.66	-0.76	-0.75	0.64	0.75	0.26	-0.49	-0.01	0.74		-0.69	-0.83	-0.38	0.91	0.84	-0.77	0.85	0.81
Short Term Investments	-0.81	0.67	-0.9	-0.86	-0.79	0.02	-0.81	0.71	-0.16	0.9	0.9	-0.15	-0.89	-0.29	0.05	0.6	-0.8	-0.69		0.7	0.67	-0.83	-0.87	0.63	-0.79	-0.78
Non Current Liabilities Total	-0.69	0.53	-0.88	-0.84	-0.92	0.21	-0.93	0.6	-0.34	0.75	0.76	-0.22	-0.74	0.08	0.44	0.23	-0.71	-0.83	0.7		0.53	-0.81	-0.92	0.99	-0.92	-0.7
Capital Lease Obligations	-0.32	1.0	-0.46	-0.45	-0.43	0.22	-0.46	0.94	0.29	0.47	0.81	-0.22	-0.43	0.45	0.11	0.89	-0.36	-0.38	0.67	0.53		-0.31	-0.63	0.54	-0.43	-0.53
Other Current Assets	0.83	-0.31	0.97	0.97	0.87	-0.09	0.87	-0.42	0.55	-0.85	-0.77	0.34	0.85	0.49	-0.21	-0.09	0.79	0.91	-0.83	-0.81	-0.31		0.87	-0.73	0.87	0.85
Other Stockholder Equity	0.74	-0.63	0.95	0.92	0.89	-0.13	0.91	-0.74	0.37	-0.84	-0.91	0.29	0.84	0.06	-0.36	-0.39	0.75	0.84	-0.87	-0.92	-0.63	0.87		-0.87	0.89	0.84
Total Liab	-0.61	0.54	-0.8	-0.76	-0.88	0.27	-0.89	0.6	-0.24	0.67	0.71	-0.16	-0.67	0.19	0.42	0.24	-0.64	-0.77	0.63	0.99	0.54	-0.73	-0.87		-0.88	-0.64
Net Invested Capital	0.91	-0.43	0.93	0.9	1.0	0.11	1.0	-0.44	0.48	-0.93	-0.7	0.21	0.93	0.16	-0.49	-0.18	0.92	0.85	-0.79	-0.92	-0.43	0.87	0.89	-0.88		0.61
Property Plant And Equipment Gross	0.5	-0.53	0.83	0.84	0.61	-0.43	0.63	-0.7	0.31	-0.59	-0.9	0.43	0.58	0.27	-0.01	-0.32	0.45	0.81	-0.78	-0.7	-0.53	0.85	0.84	-0.64	0.61

Click cells to compare fundamentals

Aligos Therapeutics Account Relationship Matchups

Aligos Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	146.5M	265.3M	235.4M	146.7M	151.5M	193.1M
Short Long Term Debt Total	14.3M	13.0M	14.5M	12.6M	11.1M	10.6M
Other Current Liab	753K	14.1M	22.5M	12.9M	13.6M	11.7M
Total Current Liabilities	13.8M	30.3M	39.0M	33.1M	23.9M	27.1M
Total Stockholder Equity	(64.9M)	220.0M	184.7M	103.9M	92.1M	95.7M
Other Liab	3.6M	4.5M	133K	233K	209.7K	199.2K
Net Tangible Assets	(64.9M)	220.0M	184.7M	103.9M	119.5M	94.6M
Property Plant And Equipment Net	16.1M	14.9M	15.0M	12.5M	9.8M	11.1M
Current Deferred Revenue	6.8M	7.9M	7.6M	9.2M	1.3M	1.2M
Net Debt	(55.2M)	(207.4M)	(172.4M)	(68.8M)	(124.6M)	(130.8M)
Retained Earnings	(66.2M)	(174.7M)	(303.1M)	(399.1M)	(486.8M)	(462.5M)
Accounts Payable	3.8M	3.3M	3.0M	4.7M	2.5M	3.7M
Cash	69.6M	220.4M	186.8M	81.3M	135.7M	131.6M
Non Current Assets Total	26.3M	15.3M	30.9M	13.1M	12.8M	15.2M
Non Currrent Assets Other	188K	(3.3M)	866K	(2.5M)	625.0K	656.2K
Other Assets	188K	7.3K	866K	634K	(2.4M)	(2.3M)
Cash And Short Term Investments	117.7M	243.5M	190.7M	125.8M	135.7M	165.8M
Common Stock Shares Outstanding	21.9M	34.2M	39.9M	42.7M	24.9M	33.9M
Short Term Investments	48.1M	23.1M	3.9M	44.5M	(70K)	(66.5K)
Liabilities And Stockholders Equity	146.5M	265.3M	235.4M	146.7M	153.9M	193.5M
Non Current Liabilities Total	197.6M	15.0M	11.7M	9.7M	35.5M	51.1M
Capital Lease Obligations	14.3M	13.0M	14.5M	12.6M	11.1M	10.6M
Other Current Assets	2.0M	6.5M	13.7M	7.7M	5.4M	6.7M
Other Stockholder Equity	(180.7M)	395.0M	487.3M	502.6M	578.3M	308.4M
Total Liab	211.4M	45.3M	50.6M	42.8M	61.8M	71.1M
Net Invested Capital	(64.9M)	220.0M	184.7M	103.9M	92.1M	95.7M
Property Plant And Equipment Gross	16.1M	14.9M	22.2M	22.1M	20.6M	20.4M
Total Current Assets	120.2M	250.0M	204.4M	133.5M	141.1M	172.6M
Accumulated Other Comprehensive Income	(115K)	(188K)	452K	401K	545K	572.3K
Net Working Capital	106.4M	219.7M	165.5M	100.4M	117.2M	145.6M
Short Term Debt	2.5M	5.0M	5.8M	6.3M	6.5M	5.0M
Property Plant Equipment	16.1M	14.9M	15.0M	4.8M	4.3M	4.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aligos Stock Analysis

When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aligos Historical Balance Sheet

About Aligos Balance Sheet Analysis

Aligos Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Aligos Therapeutics balance sheet Correlations

Aligos Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aligos Therapeutics balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Aligos Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Net Tangible Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Total Liab	+ 0.99	Non Current Liabilities Total

Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Net Debt	- 0.97	Total Assets
Net Invested Capital	- 0.93	Net Debt
Non Current Liabilities Total	- 0.93	Net Tangible Assets
Net Debt	- 0.93	Net Tangible Assets